Toshiyuki Maruyama, Hiroshi Mitsui, Kazuyuki Hanajiri, Yasuhiko Sugawara, Hiroshi Imamura, Masatoshi Makuuchi – 30 December 2003

Philippe Ichai, Emmanuel Huguet, Catherine Guettier, Daniel Azoulay, Maria Eugenia Gonzalez, Bernard Fromenty, Pascal Masnou, Faouzi Saliba, Bruno Roche, Fahed Zeitoun, Denis Castaing, Didier Samuel – 30 December 2003 – Fulminant liver failure is a rare complication of grand mal seizures with a high mortality, the prognosis being largely determined by the combination of the hepatic and neurologic insults. The mechanisms of acute liver failure secondary to grand mal epilepsy and the place of liver transplantation in this context are poorly defined and are the subject of this report.

John Tsiaoussis, Philip Noel Newsome, Leonard Joseph Nelson, Peter Clive Hayes, John Nicholas Plevris – 30 December 2003 – Liver failure, notwithstanding advances in medical management, remains a cause of considerable morbidity and mortality in the developed world. Although bioartificial liver (BAL) support systems offer the potential of significant therapeutic benefit for such patients, many issues relating to their use are still to be resolved.

Hanns‐Ulrich Marschall, Udo C.I. Oppermann, Stefan Svensson, Erik Nordling, Bengt Persson, Jan‐Olov Höög, Hans Jörnvall – 30 December 2003 – 3β‐Hydroxy (iso) bile acids are formed during enterohepatic circulation from 3α‐hydroxy bile acids and constitute normal compounds in plasma but are virtually absent in bile. Isoursodeoxycholic acid (isoUDCA) is a major metabolite of UDCA. In a recent study it was found that after administration of isoUDCA, UDCA became the major acid in bile.

Pietro E. Majno, François P. Sarasin, Gilles Mentha, Antoine Hadengue – 30 December 2003 – Two treatments are accepted for patients with solitary hepatocellular carcinoma ≤5 cm in size and with preserved hepatic function: (1) liver resection, which can be performed without delay but has a high recurrence rate, and (2) liver transplantation, which has a better long‐term survival, but is not easily available because grafts are scarce.

Albert J. Czaja, Michawl P. Manns, Ian G. Mcfarlane, Jay H. Hoofnagle – 30 December 2003

Hiroshi Okabe, Iwao Ikai, Koichi Matsuo, Seiji Satoh, Hirohito Momoi, Tatsuhiko Kamikawa, Nagato Katsura, Ryuta Nishitai, Osamu Takeyama, Manabu Fukumoto, Yoshio Yamaoka – 30 December 2003 – To examine the role of the loss of heterozygosity (LOH) in hepatitis‐related carcinogenesis, we performed a genome‐wide scan of LOH in 44 tumors of hepatocellular carcinoma (HCC) using 216 microsatellite markers throughout all human chromosomes. A high frequency of LOH (>30% of informative cases) was observed at 33 loci on chromosome arms 4q, 6q, 8p, 8q, 9p, 9q, 13q, 16p, 16q, 17p, and 19p.

John G. Pastorino, Jan B. Hoek – 30 December 2003 – In the present study, tumor necrosis factor‐α (TNF‐α) cytotoxicity is shown to be potentiated by ethanol exposure in vitroin the human hepatoma cell line, HepG2, and in rat primary hepatocytes. Exposure of HepG2 cells and primary hepatocytes for 48 hours to concentrations of ethanol ranging between 50 and 100 mmol/L significantly increased TNF‐α cytotoxicity compared with cells treated with TNF‐α alone. The cell killing was associated with, and dependent on, the development of the mitochondrial permeability transition (MPT).

Marina Berenguer, F. Xavier López‐Labrador, Harry B. Greenberg, Teresa L. Wright – 30 December 2003

Paul Glue, Regine Rouzier‐Panis, Claude Raffanel, Ron Sabo, Samir K. Gupta, Margaret Salfi, Shiela Jacobs, Robert P. Clement – 30 December 2003 – The objectives of this study were to assess the safety, pharmacokinetics, and efficacy of pegylated interferon alfa‐2b (PEG‐Intron) plus ribavirin in patients with chronic hepatitis C. A total of 72 patients (35 men/37 women, age range 20‐68 years) with clinically compensated chronic hepatitis C virus (HCV) were enrolled into this open‐label, randomized, active controlled study.